ImmunityBio Presents Long-Term Overall Survival Data In Non-Small Cell Lung Cancer Patients And Announces Registrational Intent Phase 3 Trials With ANKTIVA And Checkpoint Immunotherapy At World Conference On Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
ImmunityBio, Inc. (IBRX) presented promising Phase 2 data at the World Conference on Lung Cancer, showing prolonged survival in NSCLC patients using ANKTIVA with checkpoint inhibitors. The data supports Phase 3 trials and potential global launch.
September 09, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ImmunityBio's Phase 2 data shows ANKTIVA with checkpoint inhibitors extends survival in NSCLC patients, supporting Phase 3 trials and potential global launch.
The positive Phase 2 data for ANKTIVA in combination with checkpoint inhibitors indicates a potential breakthrough in NSCLC treatment, which could lead to successful Phase 3 trials and a global launch. This is likely to positively impact IBRX's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100